Article
High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
The Journal of rheumatology - 1 Sept 1998
Davis J C, Fessler B J, Tassiulas I O, McInnes I B, Yarboro C H, Pillemer S, Wilder R, Fleisher T A, Klippel J H, Boumpas D T
Abstract excerpt
OBJECTIVE: Fludarabine, a nucleoside analog that targets both resting and proliferating lymphocytes, is a promising drug for the treatment of autoimmune diseases. We conducted a 2 dose, open label clinical trial to evaluate the toxicity/safety of the fludarabine treatment and its clinical and immunological effects. METHODS: Twenty-six patients with severe rheumatoid arthritis (RA) refractory to treatment with at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.